H.R. 3520 (119th)Bill Overview

STAND Against Emerging Opioids Act

Crime and Law Enforcement|Crime and Law Enforcement
Cosponsors
Support
Lean Republican
Introduced
May 20, 2025
Discussions
Bill Text
Current stageCommittee

Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for co…

Introduced
Committee
Floor
President
Law
Congressional Activities
01 · The brief
Plain-English summaryWhat this bill actually does

This bill amends the Controlled Substances Act to add tianeptine — including analogues, salts, isomers, and salts of isomers — to Schedule III. The scheduling becomes effective 90 days after enactment.

Why people may split

Progressives worry about criminalization; conservatives emphasize enforcement

Watch point

Relative to its intended legislative type, this bill is a straightforward, narrowly scoped substantive amendment to the Controlled Substances Act that is mechanistically precise and provides a clear effective date, but it contains limited contextual justification, no fiscal or resourcing discussion, minimal consideration of edge cases (notably undefined "analogues"), and no added reporting or review provisions.

This bill amends the Controlled Substances Act to add tianeptine — including analogues, salts, isomers, and salts of isomers — to Schedule III.

The scheduling becomes effective 90 days after enactment.

Passage40/100

Content is narrow and administrative so chances are reasonable, but congressional calendaring, possible stakeholder opposition, and procedural hurdles reduce probability.

CredibilityAligned

Relative to its intended legislative type, this bill is a straightforward, narrowly scoped substantive amendment to the Controlled Substances Act that is mechanistically precise and provides a clear effective date, but it contains limited contextual justification, no fiscal or resourcing discussion, minimal consideration of edge cases (notably undefined "analogues"), and no added reporting or review provisions.

Contention30/100

Progressives worry about criminalization; conservatives emphasize enforcement

02 · What it does

Who stands to gain, and who may push back.

Likely benefits vs burdens50% / 50%
Federal agenciesManufacturers

These are examples from the analysis, not a ranked list of the most-affected groups.

Likely helped
  • Federal agenciesMakes manufacture and distribution without registration a federal crime, reducing unregulated market availability.
  • Potential benefitGives law enforcement clearer authority to seize products and prosecute traffickers of tianeptine.
  • Potential benefitFacilitates removal of tianeptine-containing products marketed as supplements from retail channels.
Likely burdened
  • Potential burdenMay lead to prosecutions or penalties for small sellers or individual users of tianeptine products.
  • ManufacturersImposes compliance costs on manufacturers, distributors, and retailers handling tianeptine-containing goods.
  • Potential burdenCould push remaining demand into illicit markets, reducing product quality controls and surveillance.
03 · Why people split

Why the argument around this bill splits.

Progressives worry about criminalization; conservatives emphasize enforcement
Progressive65%

Likely supportive of public-health measures that reduce opioid harm, but wary of criminalization and access barriers.

Would emphasize treatment, harm reduction, and protecting research and medical access when implementing scheduling.

Split reaction
Centrist80%

Will view this as a pragmatic regulatory response to reports of misuse.

Wants implementation details, fiscal impacts, and guardrails to avoid unintended consequences.

Leans supportive
Conservative70%

May support action that strengthens law enforcement against opioids, but cautious about expanding federal regulation and costs.

Would push for narrow scope and enforcement focus.

Leans supportive
04 · Can it pass?

The path through Congress.

Introduced

Reached or meaningfully advanced

Committee

Reached or meaningfully advanced

Floor

Still ahead

President

Still ahead

Law

Still ahead

Passage likelihood40/100

Content is narrow and administrative so chances are reasonable, but congressional calendaring, possible stakeholder opposition, and procedural hurdles reduce probability.

Scope and complexity
24%
Scopenarrow
24%
Complexitylow
Why this could stall
  • Whether regulatory agencies (DEA/FDA) have already initiated scheduling actions
  • Potential opposition from researchers or manufacturers affected by Schedule III status
05 · Recent votes

Recent votes on the bill.

No vote history yet

The bill has not accumulated any surfaced votes yet.

06 · Go deeper

Go deeper than the headline read.

Included on this page

Progressives worry about criminalization; conservatives emphasize enforcement

Content is narrow and administrative so chances are reasonable, but congressional calendaring, possible stakeholder opposition, and procedu…

Unlocked analysis

Relative to its intended legislative type, this bill is a straightforward, narrowly scoped substantive amendment to the Controlled Substances Act that is mechanistically precise and provides a clear effective date, but…

Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.

Perspective breakdownsPassage barriersLegislative design reviewStakeholder impact map
Open full analysis